Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XIAP | P98170 | 11/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR1E | P28566 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | BIRC3 | Q13489 | 4/20 | 0.37 |
| ▸ | BIRC2 | Q13490 | 12/20 | 0.36 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116957 | 0.91 | XIAP (0.41) | XIAPBIRC3BIRC2 | |
| SCHEMBL2113164 | 0.88 | XIAP (0.43) | XIAPBIRC3BIRC2 | |
| SCHEMBL2115825 | 0.88 | XIAP (0.40) | XIAPBIRC3BIRC2 | |
| SCHEMBL2115930 | 0.85 | XIAP (0.43) | XIAPBIRC3BIRC2 | |
| SCHEMBL2115282 | 0.85 | XIAP (0.40) | XIAPBIRC3BIRC2 | |
| SCHEMBL2114707 | 0.84 | XIAP (0.39) | XIAPBIRC3BIRC2 | |
| SCHEMBL2113999 | 0.83 | EPHX2 (0.35) | XIAPBIRC3BIRC2 | |
| SCHEMBL2115379 | 0.83 | ALDH1A1 (0.38) | XIAPLMNABIRC3BIRC2 | |
| SCHEMBL2114097 | 0.82 | XIAP (0.49) | XIAPBIRC3BIRC2 | |
| SCHEMBL2116974 | 0.81 | CYP3A4 (0.35) | XIAPBIRC3BIRC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2434889-B1 | IAP INHIBITORS | TETRALOGIC BIRINAPANT UK LTD (GB) | 2016-03-09 | — | — | EP | disclosed |
| US-20130274278-A1 | IAP INHIBITORS | TETRALOGIC PHARM CORP (US) | 2013-10-17 | — | — | US | disclosed |
| US-8481495-B2 | IAP inhibitors | TETRALOGIC PHARMACEUTICALS CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120094917-A1 | IAP INHIBITORS | TETRALOGIC PHARMACEUTICALS CORP (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274278-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885MEN1 2419/4885LMNA 767/4885 |
| US-20120094917-A1 | IAP INHIBITORS | XIAP, IAPP, BIRC5 | XIAP 1/4885MEN1 2419/4885LMNA 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.